Comparing Phreesia (PHR) & Its Competitors

Phreesia (NYSE:PHR) is one of 93 public companies in the “Healthcare Technology” industry, but how does it compare to its rivals? We will compare Phreesia to similar companies based on the strength of its analyst recommendations, earnings, institutional ownership, valuation, risk, dividends and profitability.

Profitability

This table compares Phreesia and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phreesia	2.06%	5.22%	3.02%
Phreesia Competitors	-778.94%	-34.14%	-15.64%

Analyst Ratings

This is a summary of recent ratings for Phreesia and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phreesia	1	10	8	0	2.37
Phreesia Competitors	446	1513	2723	88	2.51

Phreesia currently has a consensus price target of $14.07, suggesting a potential upside of 13.70%. As a group, “Healthcare Technology” companies have a potential upside of 37.31%. Given Phreesia’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Phreesia has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

92.1% of Phreesia shares are held by institutional investors. Comparatively, 42.3% of shares of all “Healthcare Technology” companies are held by institutional investors. 5.2% of Phreesia shares are held by insiders. Comparatively, 16.0% of shares of all “Healthcare Technology” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Phreesia has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Phreesia’s rivals have a beta of 1.06, suggesting that their average share price is 6% more volatile than the S&P 500.

Earnings & Valuation

This table compares Phreesia and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Phreesia	$480.59 million	$2.31 million	72.78
Phreesia Competitors	$355.95 million	-$24.15 million	13.19

Phreesia has higher revenue and earnings than its rivals. Phreesia is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Phreesia beats its rivals on 7 of the 13 factors compared.

About Phreesia

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is based in Wilmington, Delaware.